Staphylococcus aureus biofilm formation

**Staphylococcus aureus biofilm formation** refers to the process by which *S. aureus* bacteria adhere to surfaces—both biotic and abiotic—and develop multicellular communities encased within an extracellular polymeric matrix composed primarily of proteins (such as Bap), exopolysaccharides like polysaccharide intercellular adhesin/polymeric N-acetyl-glucosamine (PIA/PNAG), extracellular DNA (eDNA), and other secreted factors.[3][4][5] This process involves initial attachment mediated by surface proteins including MSCRAMMs and autolysins such as AtlA; accumulation through intercellular adhesion molecules including PIA produced via the *icaADBC* locus; maturation regulated by signaling pathways such as quorum-sensing Agr system; structural modulation via phenol-soluble modulins; and eventual dispersal.[1][3] Biofilms confer significant protection against antibiotics and host immune responses,[5] contributing substantially to chronicity in device-related infections, osteomyelitis, endocarditis, wound infections, among others. Because "biofilm formation" encompasses multiple molecular targets rather than being one itself,[3] it should be considered an umbrella term describing this collective pathogenic strategy rather than a discrete druggable entity.

Other names

S. aureus biofilmStaphylococcal biofilmBiofilm matrix of S. aureus

Drugs act by disrupting one or more components of the biofilm matrix or interfering with key regulators/processes such as: - Degradation of extracellular DNA to destabilize the matrix - Inhibition of polysaccharide synthesis/export (targeting IcaADBC operon) - Inhibition/disruption of quorum sensing systems like Agr to prevent maturation/dispersal